Contents

9 Human papillomavirus (HPV)

References

  1. Schiller JT, Lowy DR, Markowitz LE. 2013. Human papillomavirus vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition). Elsevier Saunders.
  2. American Academy of Pediatrics. 2015. Human papillomaviruses. In: Kimberlin DW, Brady MT, Jackson MA, et al (eds). Red Book: 2015 Report of the Committee on Infectious Diseases (30th edition). Elk Grove Village, IL: American Academy of Pediatrics.
  3. Saraiya M, Unger ER, Thompson TD, et al. 2015. Assessment of HPV types in cancers: Implications for current and 9-valent HPV vaccines. Journal of the National Cancer Institute 107(6). DOI: 10.1093/jnci/djv086 (accessed 14 September 2016).
  4. Wu X, Watson M, Wilson R, et al. 2012. Human papillomavirus-associated cancers – United States, 2004–2008. Morbidity and Mortality Weekly Report 61(15): 258–61. URL: www.cdc.gov/mmwr/preview/mmwrhtml/mm6115a2.htm (accessed 3 September 2013).
  5. Ministry of Health. 2007. High Grade Squamous Intra-epithelial Lesions (HSIL) in New Zealand. URL: https://www.nsu.govt.nz/system/files/resources/hsil-in-new-zealand.pdf
  6. McFadden K, McConnell D, Salmond C, et al. 2004. Socioeconomic deprivation and the incidence of cervical cancer in New Zealand: 1988–1998. New Zealand Medical Journal 117(1206): U1172.
  7. Vajdic CM, van Leeuwen MT, Jin J, et al. 2009. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sexually Transmitted Infections 85(5): 330–5.
  8. Grulich AE, van Leeuwen MT, Falster MO, et al. 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. The Lancet 370(9581): 59–67.
  9. Wilkin T, Lee JY, Lensing SY, et al. 2010. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. Journal of Infectious Diseases 202(8): 1246–53.
  10. Beachler DC, Weber KM, Margolick JB, et al. 2012. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIV-negative adults. Cancer Epidemiology Biomarkers and Prevention 21(1): 122–133. DOI: 10.1158/1055-9965.epi-11-0734 (accessed 1 January 2012).
  11. Begue R. 2012. Immunization recommendations for the HIV-infected adolescent. HIV Clinician 24(2): 15–21.
  12. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. URL: https://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult_OI.pdf (accessed 11 November 2016).
  13. Malachek DA, Poynten M, Jin F, et al. 2012. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncology 13(5): 487–500.
  14. Sarian LO, Derchain SF, Pitta Dda R, et al. 2004. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). Journal of Clinical Virology 31(4): 270–4.
  15. Safaeian M, Hildesheim A, Gonzalez P, et al. 2012. Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer. PLOS ONE 7(4): e33619. DOI: 10.1371/journal.pone.0033619 (accessed 28 August 2013).
  16. Department of Health and Ageing. 2016. Human papillomavirus. In: The Australian Immunisation Handbook (10th edition; updated August 2016). URL: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-6 (accessed 19 October 2016).
  17. Plummer M, de Martel C, Vignat J, et al. 2016. Global burden of cancers attributable to infections in 2012: a synthetic analysis. The Lancet Global Health 4(9): URL: http://www.thelancet.com/journals/langlo/article/PIIS2214-109X(16)30143-7/fulltext (accessed 4 August 2016).
  18. Winer RL, Feng Q, Hughes JP, et al. 2008. Risk of female human papillomavirus acquisition associated with first male sex partner. Journal of Infectious Diseases 197(2): 279–282.
  19. Clark TC, Fleming T, Bullen P, et al. 2013. Youth’12 Overview: The health and wellbeing of New Zealand secondary school students in 2012. URL: http://www.fmhs.auckland.ac.nz/assets/fmhs/faculty/ahrg/docs/2012-overview.pdf (accessed 24 October 2013).
  20. Clark TC, Fleming T, Bullen P, et al. 2013. Youth’12 Prevalence Tables: The health and wellbeing of New Zealand secondary school students in 2012. URL: https://www.fmhs.auckland.ac.nz/assets/fmhs/faculty/ahrg/docs/2012prevalence-tables-report.pdf (accessed 24 October 2013).
  21. Clark TC, Lucassen MF, Fleming T, et al. 2016. Changes in the sexual health behaviours of New Zealand secondary school students, 2001–2012: findings from a national survey series. Australian and New Zealand Journal of Public Health 40(4): 329–36. DOI: 10.1111/1753-6405.12543 (accessed 11 July 2016).
  22. Kang Y-J, Lewis H, Smith MA, et al. 2015. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand. BMC Infectious Diseases 15(365). DOI: 10.1186/s12879-015-1034-5 (accessed 15 October 2016).
  23. Simonella LM, Lewis H, Smith MA, et al. 2013. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infectious Diseases 13: 114. URL: http://www.biomedcentral.com/1471-2334/13/114 (accessed 14 September 2016).
  24. Sykes P, Gopala K, Tan AL, et al. 2014. Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. BMC Infectious Diseases 14: 374. URL: http://www.biomedcentral.com/1471-2334/14/374 (accessed 14 September 2016).
  25. Ministry of Health. 2016. Selected Cancers 2013, 2014, 2015 (Provisional). URL: http://www.health.govt.nz/publication/selected-cancers-2013-2014-2015 (accessed 8 December 2016).
  26. Ministry of Health. 2016. Cancer: New registrations and deaths 2013. URL: http://www.health.govt.nz/publication/cancer-new-registrations-and-deaths-2013 (accessed 8 December 2016).
  27. Wiley DJ, Douglas J, Beutner K, et al. 2002. External genital warts: diagnosis, treatment, and prevention. Clinical Infectious Diseases 35(Supp. 2): S210–24.
  28. Koutsky LA. 1997. Epidemiology of genital human papillomavirus infection. American Journal of Medicine 102(5A): 3–8.
  29. Kjaer SK, Tran TN, Sparen P, et al. 2007. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. Journal of Infectious Diseases 196(10): 1447–54.
  30. Institute of Environmental Science and Research Ltd. 2010. Sexually Transmitted Infections in New Zealand: Annual surveillance report 2009. URL: https://surv.esr.cri.nz/surveillance/annual_sti.php?we_objectID=2316 (accessed 17 November 2016).
  31. Institute of Environmental Science and Research Ltd. 2016. STI Clinic Surveillance: Quarterly Reports Jan–Mar 2016. URL: https://surv.esr.cri.nz/surveillance/quarterly_sticlinic.php?we_objectID=4382 (accessed 17 November 2016).
  32. Wilson N, Morgan J, Baker MG. 2014. Evidence for effectiveness of a national HPV vaccination programme: national prescription data from New Zealand. Sexually Transmitted Infections 90(2): DOI: 10.1136/sextrans-2013-051037 (accessed 5 September 2016).
  33. MacIntyre CR, Shaw P, Mackie FE, et al. 2016. Immunogenicity and persistence of immunity of a quadrivalent human papillomavirus (HPV) vaccine in immunocompromised children. Vaccine 34(36): 4343–50.
  34. Gomez-Lobo V, Whyte T, Kaufman S, et al. 2014. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Pediatric Transplantation 18(3): 310–15.
  35. Giacomet V, Penagini F, Trabattoni D, et al. 2014. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 32(43): 5657–61.
  36. Kahn JA, Xu J, Kapogiannis BG, et al. 2013. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clinical Infectious Diseases 57(5): 735–44.
  37. Kojic EM, Kang M, Cespedes MS, et al. 2014. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clinical Infectious Diseases 59(1): 127–35.
  38. Jacobson DL, Bousvaros A, Ashworth L, et al. 2013. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflammatory Bowel Disease 19(7): 1441–9. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3677764/ (accessed 4 September 2016).
  39. Kumar D, Unger ER, Panicker G, et al. 2013. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. American Journal of Transplantation 13(9): 2411–7. DOI: 10.1111/ajt.12329 (accessed 4 September 2016).
  40. Joura EA, Kjaer SK, Wheeler CM, et al. 2008. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26(52): 6844–51.
  41. Einstein MH, Baron M, Levin MJ, et al. 2009. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Human Vaccines 5(10): 705–19.
  42. Rowhani-Rahbar A, Alvarez FB, Bryan JT, et al. 2012. Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. Journal of Clinical Virology 53(3): 239–43.
  43. K. M. Donken R, Bogaards JA, et al. 2015. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. Journal of Infection 71(1): 61–73. DOI: http://dx.doi.org/10.1016/j.jinf.2015.02.005 (accessed 4 September 2016).
  44. Sankaranarayanan R, Prabhu PR, Pawlita M, et al. 2016. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. The Lancet Oncology 17(1): 67–77. DOI: http://dx.doi.org/10.1016/S1470-2045(15)00414-3 (accessed 4 September 2016).
  45. Joura EA, Giuliano AR, Iversen O-E, et al. 2015. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 372(8): 711–23. DOI: 10.1056/NEJMoa1405044 (accessed 4 September 2016).
  46. Vesikari T, Brodszki N, van Damme P, et al. 2015. A randomized, double-blind, phase III study of the immunogenicity and safety of a 9-valent human papillomavirus L1 virus-like particle vaccine (V503) versus gardasil in 9–15-year-old girls. Pediatric Infectious Disease Journal 34(9): 992–8. DOI: 10.1097/INF.0000000000000773 (accessed 4 September 2016).
  47. Castellsagué X, Giuliano AR, Goldstone S, et al. 2015. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine 33(48): 6892–901.
  48. Van Damme P, Olsson S, Block S, et al. 2015. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics 136(1): e28–39. URL: http://pediatrics.aappublications.org/content/136/1/e28 (accessed 28 August 2016).
  49. Seqirus/MSD. 2016. Gardasil 9 Data Sheet. URL: http://www.medsafe.govt.nz/profs/datasheet/g/gardasil9inj.pdf (accessed 4 September 2016).
  50. Lehtinen M, Paavonen J, Wheeler CM, et al. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology 13(1): 89–99.
  51. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 356(19): 1915–27.
  52. Giuliano AR, Palefsky JM, Goldstone S, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. [Erratum appears in New England Journal of Medicine 2011; 364(15): 1481]. New England Journal of Medicine 364(5): 401–11.
  53. Palefsky JM, Giuliano AR, Goldstone S, et al. 2011. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. New England Journal of Medicine 365(17): 1576–85.
  54. Swedish KA, Factor SH, Goldstone SE. 2012. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clinical Infectious Diseases 54(7): 891–8.
  55. Garland SM, Kjaer SK, Muñoz N, et al. 2016. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of ten years of real-world experience. Clinical Infectious Diseases 53(4): 519–27. DOI: 10.1093/cid/ciw354 (accessed 5 September 2016).
  56. Chow EPF, Machalek DA, Tabrizi SN, et al. 2016. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Lancet Infectious Diseases June 6. DOI: http://dx.doi.org/10.1016/S1473-3099(16)30116-5 (accessed 28 September 2016).
  57. Donovan B, Franklin N, Guy R, et al. 2011. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. The Lancet Infectious Diseases 11(1): 39–44.
  58. Read TRH, Hocking JS, Chen MY, et al. 2011. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections 87(7): 544–7.
  59. D. J. Chow EPF, Fehler G, et al. 2015. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study. Lancet Infectious Diseases 15(11): 1314–23. DOI: 10.1016/S1473-3099(15)00055-9 (accessed 28 September 2016).
  60. Joura EA, Garland SM, Paavonen J, et al. 2012. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. British Medical Journal 344: e1401. DOI: http://dx.doi.org/10.1136/bmj.e1401 (accessed 29 October 2012).
  61. Miltz A, Price H, Shahmanesh M, et al. 2014. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS ONE 9(3): e90348. DOI: 10.1371/journal.pone.0090348 (accessed 24 September 2016).
  62. World Health Organization. 2014. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiological Record 89(43): 465–92. URL: http://www.who.int/wer/2014/wer8943.pdf?ua=1 (accessed 4 September 2016).
  63. European Medicines Agency. 2016. Gardasil 9: EPAR Summary for the Public. URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003852/WC500189114.pdf (accessed 5 September 2016).
  64. Ministry of Health. 2016. National Standards for Vaccine Storage and Transportation for Immunisation Providers 2016. URL: www.health.govt.nz/coldchain
  65. Petrosky E, Bocchini JA Jr, Hariri S, et al. 2015. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 64(11): 300–4. URL: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6411a3.htm (accessed 26 August 2016).
  66. Muñoz N, Manalastas R, Pitisuttithum P, et al. 2009. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. The Lancet 373(9679): 1949–57.
  67. Bonde U, Joergensen JS, Lamont RF, et al. 2016. Is HPV vaccination in pregnancy safe? Human vaccines & immunotherapeutics 12(8): 1960–4.
  68. Moreira ED Jr, Block SL, Ferris D, et al. 2016. Safety profile of the 9-valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics 138(2): e20154387. DOI: 10.1542/peds.2015-4387 (accessed 18 October 2016).
  69. Chao C, Klein NP, Velicer CM, et al. 2012. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine 271(2): 193–203. DOI: 10.1111/j.1365-2796.2011.02467.x (accessed 29 October 2012).
  70. Arnheim-Dahlstroem L, Pasternak B, Svanstroem H, et al 2013. Autoimmune, neurological and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. British Medical Journal 247: f5906. DOI: 10.1136/bmj.f5906 (accessed 10 December 2016).
  71. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. 2014. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. Journal of Internal Medicine 275(4): 398–408. DOI: 10.1111/joim.12155 (accessed 10 December 2016).
  72. Langer-Gould A, Qian L, Tartof SY, et al. 2014. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating disease. JAMA Neurology 71(12): 1506–13. DOI: 10.1001/jamaneurol.2014.2633 (accessed 10 December 2016).
  73. Scheller NM, Svanström H, Pasternak B, et al. 2015. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating disease of the central nervous system. Journal of the Americal Medical Association 313(1): 54–61. DOI: 10.1001/jama.2014.16946 (accessed 10 December 2016).
  74. Nguyen M, Ball R, Midthun K, et al. 2012. The Food and Drug Administration's post-licensure rapid immunization safety monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiology and Drug Safety 21(Suppl 1): 291–297. DOI: 10.1002/pds.2323 (accessed 26 December 2012).
  75. Kliewer EV, Demers AA, Brisson M, et al. 2010. The Manitoba human papillomavirus vaccine surveillance and evaluation system. [Erratum appears in Health Reports 2010; 21(3): 77]. Health Reports 21(2): 37–42.
  76. Gold MS, McIntyre P. 2010. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sexual Health 7(3): 320–4.
  77. World Health Organization. 2013. Global Advisory Committee on Vaccine Safety, 12–13 June 2013. Weekly Epidemiological Record 88(29): 301–12. URL: www.who.int/vaccine_safety/committee/reports/wer8829.pdf (accessed 4 November 2013).
  78. World Health Organization. 2016. Meeting of the Strategic Advisory Group of Experts on immunization, April 2016 – conclusions and recommendations. Weekly Epidemiological Record 91(21): 266–84. URL: http://www.who.int/wer/2016/wer9121.pdf?ua=1 (accessed 12 October 2016).
  79. Klein NP, Hansen J, Chao C, et al. 2012. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Archives of Pediatrics and Adolescent Medicine 166(12): 1140–1148. DOI: 10.1001/archpediatrics.2012.1451 (accessed 26 December 2012).